Literature DB >> 15047504

P glycoprotein in human immunodeficiency virus type 1 infection and therapy.

Sanjay U C Sankatsing1, Jos H Beijnen, Alfred H Schinkel, Joep M A Lange, Jan M Prins.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15047504      PMCID： PMC375313          DOI： 10.1128/AAC.48.4.1073-1081.2004

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  154 in total

1.  Domain mapping of the photoaffinity drug-binding sites in P-glycoprotein encoded by mouse mdr1b.

Authors:  L M Greenberger; C J Lisanti; J T Silva; S B Horwitz
Journal:  J Biol Chem       Date:  1991-11-05       Impact factor: 5.157

2.  The functional purification of P-glycoprotein is dependent on maintenance of a lipid-protein interface.

Authors:  R Callaghan; G Berridge; D R Ferry; C F Higgins
Journal:  Biochim Biophys Acta       Date:  1997-09-04

3.  Function of P-glycoprotein expressed in placenta and mole.

Authors:  Y Nakamura; S Ikeda; T Furukawa; T Sumizawa; A Tani; S Akiyama; Y Nagata
Journal:  Biochem Biophys Res Commun       Date:  1997-06-27       Impact factor: 3.575

4.  Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy.

Authors:  T W Chun; L Stuyver; S B Mizell; L A Ehler; J A Mican; M Baseler; A L Lloyd; M A Nowak; A S Fauci
Journal:  Proc Natl Acad Sci U S A       Date:  1997-11-25       Impact factor: 11.205

5.  P-170 glycoprotein (P-170) is involved in the impairment of natural killer cell-mediated cytotoxicity in HIV+ patients.

Authors:  M B Lucia; R Cauda; W Malorni; G Rainaldi; M Tumbarello; E Tacconelli; C Rumi; G Donelli; L Ortona
Journal:  Immunol Lett       Date:  1995-09       Impact factor: 3.685

6.  Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir.

Authors:  D J Kempf; K C Marsh; G Kumar; A D Rodrigues; J F Denissen; E McDonald; M J Kukulka; A Hsu; G R Granneman; P A Baroldi; E Sun; D Pizzuti; J J Plattner; D W Norbeck; J M Leonard
Journal:  Antimicrob Agents Chemother       Date:  1997-03       Impact factor: 5.191

7.  Evidence for two nonidentical drug-interaction sites in the human P-glycoprotein.

Authors:  S Dey; M Ramachandra; I Pastan; M M Gottesman; S V Ambudkar
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-30       Impact factor: 11.205

8.  Stereoisomers of calcium antagonists which differ markedly in their potencies as calcium blockers are equally effective in modulating drug transport by P-glycoprotein.

Authors:  V Höllt; M Kouba; M Dietel; G Vogt
Journal:  Biochem Pharmacol       Date:  1992-06-23       Impact factor: 5.858

9.  Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group.

Authors:  A Mocroft; S Vella; T L Benfield; A Chiesi; V Miller; P Gargalianos; A d'Arminio Monforte; I Yust; J N Bruun; A N Phillips; J D Lundgren
Journal:  Lancet       Date:  1998-11-28       Impact factor: 79.321

Review 10.  Natural killer cell function in patients with acquired immunodeficiency syndrome and related diseases.

Authors:  B G Brenner; A Dascal; R G Margolese; M A Wainberg
Journal:  J Leukoc Biol       Date:  1989-07       Impact factor: 4.962
View more
  19 in total

1.  HIV-1 Alters Intestinal Expression of Drug Transporters and Metabolic Enzymes: Implications for Antiretroviral Drug Disposition.

Authors:  Olena Kis; Sumathi Sankaran-Walters; M Tozammel Hoque; Sharon L Walmsley; Satya Dandekar; Reina Bendayan
Journal:  Antimicrob Agents Chemother       Date:  2016-04-22       Impact factor: 5.191

2.  Developmental regulation of P-glycoprotein activity within thymocytes results in increased anti-HIV protease inhibitor activity.

Authors:  Soichi Haraguchi; Sarah K Ho; Matthew Morrow; Maureen M Goodenow; John W Sleasman
Journal:  J Leukoc Biol       Date:  2011-04-19       Impact factor: 4.962

3.  Pharmacokinetics of tenofovir disoproxil fumarate and ritonavir-boosted saquinavir mesylate administered alone or in combination at steady state.

Authors:  Gregory E Chittick; Jian Zong; M Robert Blum; Jeffrey J Sorbel; John A Begley; Nathalie Adda; Brian P Kearney
Journal:  Antimicrob Agents Chemother       Date:  2006-04       Impact factor: 5.191

4.  HIV/AIDS patients display lower relative bioavailability of efavirenz than healthy subjects.

Authors:  Jackson K Mukonzo; Sarah Nanzigu; Dinko Rekić; Paul Waako; Daniel Röshammar; Michael Ashton; Jasper Ogwal-Okeng; Lars L Gustafsson; Eleni Aklillu
Journal:  Clin Pharmacokinet       Date:  2011-08       Impact factor: 6.447

5.  The effects of human immunodeficiency virus infection on the expression of the drug efflux proteins P-glycoprotein and breast cancer resistance protein in a human intestine model.

Authors:  Kelstan Ellis; Jerry W Marlin; Tracey A H Taylor; Sylvia Fitting; Kurt F Hauser; Greg Rice; MaryPeace McRae
Journal:  J Pharm Pharmacol       Date:  2014-12-31       Impact factor: 3.765

6.  Population pharmacokinetics of lopinavir in combination with rifampicin-based antitubercular treatment in HIV-infected South African children.

Authors:  Doaa Elsherbiny; Yuan Ren; Helen McIlleron; Gary Maartens; Ulrika S H Simonsson
Journal:  Eur J Clin Pharmacol       Date:  2010-06-16       Impact factor: 2.953

7.  No evidence for induction of ABC transporters in peripheral blood mononuclear cells in humans after 14 days of efavirenz treatment.

Authors:  Jürgen Burhenne; Anne-Kathrin Matthée; Ivana Pasáková; Claudia Röder; Tilman Heinrich; Walter Emil Haefeli; Gerd Mikus; Johanna Weiss
Journal:  Antimicrob Agents Chemother       Date:  2010-07-26       Impact factor: 5.191

8.  Drug-drug interaction analysis of pyronaridine/artesunate and ritonavir in healthy volunteers.

Authors:  Carrie A Morris; Luis Lopez-Lazaro; Donald Jung; Janthima Methaneethorn; Stephan Duparc; Isabelle Borghini-Fuhrer; Rolf Pokorny; Chang-Sik Shin; Lawrence Fleckenstein
Journal:  Am J Trop Med Hyg       Date:  2012-03       Impact factor: 2.345

9.  Interaction of Rifampin and Darunavir-Ritonavir or Darunavir-Cobicistat In Vitro.

Authors:  Owain Roberts; Saye Khoo; Andrew Owen; Marco Siccardi
Journal:  Antimicrob Agents Chemother       Date:  2017-04-24       Impact factor: 5.191

10.  Bayesian survival analysis in genetic association studies.

Authors:  Ioanna Tachmazidou; Toby Andrew; Claudio J Verzilli; Michael R Johnson; Maria De Iorio
Journal:  Bioinformatics       Date:  2008-07-09       Impact factor: 6.937
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.